News 2014

NIH to Fund CogRx’s Strong Molecule Soluble Abeta Receptor Antagonist Program for Treatment of AD

PITTSBURGH, May 21, 2014 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer’s disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH …

NIH to Fund CogRx’s Strong Molecule Soluble Abeta Receptor Antagonist Program for Treatment of AD Read More »

Cognition Therapeutics, Inc. (CogRx) receives a US Patent for a Drug to Fight Alzheimer’s Disease

PITTSBURGH, April 1, 2014 /PRNewswire/ –Patent describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer’s disease. CogRx has pioneered the use of disease-relevant screening technology that closely models the pathology of neurodegenerative diseases and novel, high-quality …

Cognition Therapeutics, Inc. (CogRx) receives a US Patent for a Drug to Fight Alzheimer’s Disease Read More »

Scroll to Top